Form 4: Boston Scientific CEO Michael Mahoney Executes Stock Options and Sells Shares Under 10b5-1 Plan
SEC Form 4
Michael Mahoney, Chairman, President & CEO of Boston Scientific, exercised stock options and sold shares of common stock under a pre-established Rule 10b5-1 trading plan.
Summary
- On September 5, 2024, Michael Mahoney, the Chairman, President & CEO of Boston Scientific, executed stock options to acquire 56,211 shares at $17.26 and 55,675 shares at $16.31.
- Concurrently, Mahoney sold 162,777 shares of Boston Scientific common stock at a weighted average price of $81.1696.
- These transactions were executed under a pre-established Rule 10b5-1 trading plan adopted on February 28, 2024.
- Following these transactions, Mahoney directly owns 1,622,987 shares of common stock and indirectly owns 209,278 shares through a trust.
- He also holds options to purchase 281,057 shares at $17.26 and 111,351 shares at $16.31.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The transactions are part of a pre-planned trading strategy, and there's no indication of unusual activity or concerns about the company's performance.
Positives
- The transactions were conducted under a pre-established Rule 10b5-1 trading plan, which is a legal and transparent way for insiders to trade company stock.
Industry Context
Insider transactions are common, and the use of a 10b5-1 plan suggests a planned and orderly approach to stock sales. Investors often monitor insider activity for signals about a company's prospects, but 10b5-1 plans mitigate the risk of trades being based on non-public information.
Comparison to Industry Standards
- Stock option grants and exercises are standard compensation practices for executives in publicly traded companies, including Boston Scientific's competitors such as Medtronic (MDT), Abbott Laboratories (ABT), and Johnson & Johnson (JNJ).
- The use of Rule 10b5-1 trading plans is also a common practice among executives at these companies to manage their stock holdings and avoid accusations of insider trading.
- The size and frequency of these transactions are typical for a CEO of a company the size of Boston Scientific.
Stakeholder Impact
- The stock sale could have a minor, temporary impact on the stock price, but the pre-planned nature of the transactions should mitigate any significant concerns for shareholders.
- Employees are unlikely to be directly affected by these transactions.
Key Dates
| Date | Description |
|---|---|
| 02/23/2016 | First anniversary of the date of grant for stock options vesting in four equal annual installments. |
| 02/22/2017 | First anniversary of the date of grant for stock options vesting in four equal annual installments. |
| 02/28/2024 | Date of adoption of the Rule 10b5-1 trading plan. |
| 09/05/2024 | Date of stock option exercise and stock sale transactions. |
| 09/06/2024 | Date of signature of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.